Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biyuanshu Oral Liquid is an approved traditional Chinese medicine (TCM) herbal formulation developed and marketed by Chengdu HuaSun Technology Group in China. It is specifically indicated for the treatment of rhinitis and sinusitis, including both acute and chronic forms as well as paranasal sinusitis. The formulation is composed of 13 traditional Chinese medicinal herbs, including *Xanthium sibiricum*, *Magnolia biondii*, *Mentha*, and *Scutellaria baicalensis*. According to TCM principles, the drug functions by dispersing wind, clearing heat, eliminating dampness, and opening nasal passages. It is clinically used to relieve symptoms such as nasal congestion and thick yellow nasal discharge associated with lung meridian wind-heat and gallbladder heat patterns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biyuanshu Oral Liquid.